Slate Asset Management Appoints Bozena Jankowska as Managing Director and Global Head of ESG
23.11.2021 11:00:00 EET | Business Wire | Press release
Slate Asset Management ("Slate" or “the firm”), a global alternative investment platform focused on real estate, today announced that it has appointed Bozena Jankowska as Managing Director and Global Head of Environmental, Social and Governance (“ESG”), based in Slate’s London office.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211123005469/en/
Bozena Jankowska, Managing Director and Global Head of ESG at Slate Asset Management (Photo: Business Wire)
Jankowska has nearly two decades of experience at the intersection of finance and corporate responsibility. She will lead the development of best-in-class ESG practices and policies aimed at safeguarding the long-term performance of Slate’s global investments. Additionally, Jankowska will oversee and advance Slate’s corporate social responsibility strategy and the integration of ESG into Slate’s investment and asset management processes, as well as stakeholder communications and reporting. Her focus over the next year will be to complete an ESG assessment of Slate’s assets under management, with an initial focus on Europe, before subsequently expanding to the entirety of Slate’s global platform.
“We are very pleased to welcome Bozena to our team,” said Brady Welch, Founding Partner at Slate. “From the outset, Bozena’s commitment to innovation and her entrepreneurial spirit set her apart from other candidates. She led the drive for sustainability in the finance industry well before it became mainstream, and her deep-rooted technical knowledge of complex global sustainability topics will be extremely valuable as we continue driving our ESG strategy forward.”
Blair Welch, Founding Partner at Slate Asset Management, added: “We understand that having sound ESG practices underpinning our approach to investment and asset management benefits our tenants, our communities and our investors. Bozena’s appointment displays our deep commitment to embedding ESG principles across our business.”
Jankowska was Global Co-Head of ESG at Allianz Global Investors (“AGI”), responsible for ESG integration across the firm’s investment portfolio. During her 15-year tenure at AGI, she pioneered a number of innovative ESG strategies and processes, establishing a global ESG team and growing AGI’s total sustainable investment assets under management from €70 million to over €30 billion. She also designed, managed and marketed the Allianz Global Investors clean technology fund – Global Ecotrends – which grew from $10 million in seed funding to $1 billion in assets under management, becoming a global franchise for the firm.
After leaving AGI, Jankowska founded a successful women’s sustainable fashion label, overseeing the brand’s business strategy and creative direction, including sustainable materials research and sourcing, supply chain management, and successful partnerships with non-governmental organizations focused on environmental sustainability.
“I am excited to join an organization that clearly understands how best-in-class ESG practices can play a critical role in long-term value creation,” said Jankowska. “I look forward to working with the team at Slate to continue raising the bar on the firm’s ESG performance and identifying new and innovative ways to add further rigor to our ESG approach.”
Jankowska holds a Bachelor of Science in Environmental Science from the University of Sussex. She completed her Master of Science in Environment Technology with distinction at Imperial College.
Jankowska joined Slate on November 22.
About Slate Asset Management
Slate Asset Management is a global alternative investment platform focused on real estate. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities. Visit slateam.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005469/en/
Contact information
Slate Asset Management
Karolina Kmiecik
Karolina@slateam.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
